<DOC>
	<DOCNO>NCT00040560</DOCNO>
	<brief_summary>The purpose study investigate safety image ability 111In-DAC used planar SPECT image detection lung cancer brain cancer consistent metastatic lung cancer .</brief_summary>
	<brief_title>Study 111In-DAC Medical Imaging Agent Lung Cancer Brain Cancer Consistent With Metastatic Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Inclusion Criteria Patients eligible study : Are male nonpregnant , nonlactating female 18 year age old ( must agree use appropriate effective method birth control study 2 week study ) Have ECOG performance status Zero One Are evaluate know suspect nonsmallcell lung cancer ( NSCLC ) , know brain lesion consistent metastatic lung cancer ( For NSCLC patient ) Have previously schedule biopsy surgical excision suspect NSCLC , pathological diagnosis lung cancer within 2 month enrollment receive previous treatment ( For brain cancer patient ) Have clinical sign symptom consistent primary NSCLC histological cytopathological confirmation . Patients receive previous treatment radiation brain . Have sign inform consent form Exclusion Criteria Patients eligible study : Have history suspicion significant allergic reaction anaphylaxis 111InDAC component Have clinically unstable medical condition opportunistic infection , lifethreatening disease state , impair renal hepatic function immunosuppressed Are take take part investigational study within 30 day start study Have receive indium agent within 30 day start study Are able remain immobile scanning time Have take drug may damage kidney within 2 week start study Have abnormal laboratory test result : hemoglobin &lt; 9.5 gms/dl , serum creatinine &gt; 1.5mg/100ml , alkaline phosphatase 2X upper limit normal Have undergone excisional and/or needle localization biopsy within 4 day prior study drug administration Have undergo PET scan within 7 day prior study drug administration Have active previously treat second malignancy except carcinoma situ uterine cervix nonmelanoma skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2003</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Metastatic Brain Cancer</keyword>
</DOC>